N-Palmitoyl Ethanol Amide Pharmacological Treatment in Patients With Nonsurgical Lumbar Radiculopathy
Chirchiglia D, Della Torre A, Signorelli F
Published in Journal of Clinical Pharmacology
Methodology
Randomized controlled study of ultramicronised palmitoylethanolamide added to standard care in patients with non-surgical lumbar radiculopathy, with VAS pain scores assessed over treatment and follow-up to 24 months.
Key Findings
Ultramicronised palmitoylethanolamide reduced pain intensity in patients with non-surgical lumbar radiculopathy, with benefit maintained through long-term follow-up and no significant adverse events reported.
Conclusions
In conclusion we evaluated the role of um-PEA in patients with lumbar radiculopathy with a long-term follow-up (24 months) and put in evidence the effectiveness and the safety of this formulation in patients with mild and moderate pain.
Limitations
Open methodology with limited blinding detail, single-centre recruitment, subjective pain endpoint, and long-term follow-up vulnerable to attrition and natural history of radiculopathy.
Supplements Studied
Ultramicronised palmitoylethanolamide reduced pain intensity in patients with non-surgical lumbar radiculopathy, with benefit maintained through long-term follow-up and no significant adverse events reported.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.